Neurotoxicity associated with chimeric antigen receptor T-cell therapy Chimeric antigen receptor T cell (CAR-T) therapy involves reengineering patient-derived or donor-derived T cells to express a synthetic CAR that can recognise specific cell-surface antigens, independe...

CAR-T therapy has transformed hematologic cancers, but ICANS remains a major barrier. Diverse neurotoxicities, lack of biomarkers, and unclear mechanisms highlight an urgent unmet need. #CART #Neurotoxicity #crackingICANS

Check out the paper below 👇

www.jni-journal.com/article/S016...